Proprietary Protein Platform
IPLEX® is a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug was approved in the United States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency, and is currently being supplied to a limited number of patients with Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig's disease, while supplies are available. Insmed also provides support for the development of IPLEX in Retinopathy of Prematurity (ROP).
